Back to companies

Fate Therapeutics Inc: Overview

Fate Therapeutics Inc (Fate Therapeutics) is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders. The company’s pipeline includes various off-the-shelf, iPSC-derived cellular immunotherapies for the treatment of several hematological malignancies and advanced solid tumors. Its pipeline also includes a donor-derived cell product candidate for the treatment of hematological malignancies. Fate uses its proprietary human-induced pluripotent stem cell (iPSC) platform for product development. The company also has research collaborations with companies, academic centers, and medical centers for the advancement of products and technologies. Fate Therapeutics is headquartered in San Diego, California, the US.

Headquarters United States of America

Address 12278 Scripps Summit Drive, San Diego, California, 92131


Telephone 1 858 8751803

No of Employees 449

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange FATE (NASD)

Revenue (2020) $55.8M 77.7% (2020 vs 2019)

EPS XXX

Net Income (2020) XXX -22.4% (2020 vs 2019)

Market Cap* $3.3B

Net Profit Margin (2020) XXX 31.1% (2020 vs 2019)

* As of and is in US$

Access premium data and analytics for Fate Therapeutics Inc

60+

Catalyst Calendar

Proactively evaluate Fate Therapeutics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

30+

Pipeline Drugs

Identify which of Fate Therapeutics Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Fate Therapeutics Inc’s relevant decision makers and contact details.

20+

Clinical Trials

Determine Fate Therapeutics Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

7

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

5

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

30+

Install Base

Install Base provides the user with a holistic as well as granular level view of the product deployments of leading vendors across geographies and sectors. Using the tool users can also get an understanding of various vendors’ products or solutions deployed by a prospect.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Pipeline: ProTume
Off-the-shelf, iPSC-derived Cellular Immunotherapies:
FT516 for AML and B-cell Lymphoma
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Contracts/Agreements In June, the company expanded its off-the-shelf, iPSC-derived, cell-based cancer immunotherapy collaboration with ONO Pharmaceutical Co., Ltd to include the development of chimeric antigen receptor (CAR) NK cell collaboration candidates.
2022 Regulatory Approval In January, the company secured approval from FDA for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate.
2021 Regulatory Approval In December, the company announced U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to FT516 for the treatment of relapsed / refractory diffuse large B-cell lymphoma (DLBCL).
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Fate Therapeutics Inc Johnson & Johnson Novartis AG Bristol-Myers Squibb Co Sanofi
Headquarters United States of America United States of America Switzerland United States of America France
City San Diego New Brunswick Basel New York Paris
State/Province California New Jersey - New York -
No. of Employees 449 141,700 108,000 32,200 95,442
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
William Rastetter, Ph.D. Chairman Executive Board 2011 73
J. Scott Wolchko Chief Executive Officer; Director; President Executive Board 2015 51
Edward Dulac Chief Financial Officer Senior Management 2020 47
Yu-Waye (Wayne) Chu, M.D. Chief Medical Officer Senior Management 2022 54
Bahram Valamehr, Ph.D. Chief Research and Development Officer Senior Management 2021 45
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer